Salmeter

Quick links to important sections

Salmeter

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Salmeter

What is Salmeter and What Class of Medicine is it?

The medicine known as Salmeter contains the active substance Salmeterol, a synthetic organic compound that functions as a highly selective bronchodilator delivered via inhalation. The active ingredient is formally classified as a long-acting selective beta-2 adrenergic receptor agonist (LABA). This designation means the compound selectively targets specific receptors in the lungs to sustain an effect for approximately twelve hours. Salmeterol is intended for prescription-only use, and its prolonged duration enables its role as a key maintenance therapy.

Composition and Pharmaceutical Form

The medication is administered via the inhalation route, ensuring the active substance, often formulated as Salmeterol xinafoate, reaches the smooth muscle of the airways directly. Salmeter is typically presented in one of two dosage forms: either an inhalation powder, which relies on an inert powder carrier such as lactose, or a metered-dose inhaler (MDI) aerosol, which utilizes a propellant for delivery. The use of inhaled Salmeterol is a recognized practice for targeting the lungs directly to achieve a localized effect.

General Purpose: Maintenance of Airway Function

The fundamental purpose of Salmeter is to promote smooth muscle relaxation in the bronchial tubes, which results in the widening of the airways, known as bronchodilation. This sustained action is designed for long-lasting maintenance, offering continuous support to help prevent the tightening of air passages over a twelve-hour period. This mechanism makes it a component in the scheduled, daily management of stable breathing capacity, used in adult and pediatric patients who require ongoing relief of bronchospasm.

Regulatory References

  1. Salmeterol - StatPearls - NCBI Bookshelf - NIH
  2. Beta2-Agonists - StatPearls - NCBI Bookshelf - NIH
  3. Fluticasone Propionate and Salmeterol Inhalation Powder - Contraindications (Lactose)

What side effects are possible with Salmeter?

Safety Warnings and Adverse Reactions

Black Box Warning: Long-acting beta-adrenergic agonists (LABA), such as salmeterol, when used alone (monotherapy) for the treatment of asthma, increase the risk of asthma-related death and may increase the risk of asthma-related hospitalization in children and adolescents. For asthma treatment, salmeterol must be used only in combination with an inhaled corticosteroid.

Serious and Clinically Significant Reactions

Salmeterol is contraindicated for the primary treatment of acute episodes of bronchospasm (acute asthma attacks or COPD exacerbations). Immediate use of a short-acting rescue inhaler is necessary for acute symptoms. Severe adverse reactions include paradoxical bronchospasm (sudden worsening of breathing after inhalation), which is potentially life-threatening, and serious allergic reactions (hypersensitivity) including anaphylaxis, angioedema, rash, and urticaria.

Significant cardiovascular effects are associated with salmeterol use, including palpitations, tachycardia (fast heart rate), hypertension, and cardiac arrhythmias (irregular heartbeat). Additionally, treatment may cause metabolic disturbances such as hypokalemia (low potassium) and hyperglycemia (high blood sugar).

Common Adverse Reactions

The most frequently reported adverse events are generally related to the nervous and musculoskeletal systems. These commonly include headache and tremor (shakiness). Other common reactions are dizziness, nervousness, flu-like symptoms, and musculoskeletal pain, including joint pain and muscle cramps/spasm.

Population-Specific Safety Considerations

Pediatric Patients: The use of salmeterol monotherapy for asthma is associated with an increased risk of asthma-related hospitalization in this population. Geriatric Patients: Caution is advised, as elderly patients may have a greater likelihood of underlying cardiovascular or hepatic conditions that could be worsened or alter the drug's clearance. Patients with Coexisting Conditions: Caution is necessary in individuals with cardiovascular disorders, convulsive disorders, thyrotoxicosis (overactive thyroid), diabetes mellitus, or ketoacidosis, due to the potential for exacerbation of these conditions.

Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) is generally not recommended due to increased systemic salmeterol exposure and a potential rise in cardiovascular adverse effects.

Overdose and Emergency Response

An overdose of Salmeterol is primarily characterized by the documented effects of excessive beta-adrenergic stimulation, which may manifest as an exaggeration of its expected systemic activity. Documented clinical signs include severe cardiovascular symptoms such as tachycardia (heart rates up to 200 beats per minute), palpitations, and arrhythmias. Other neurological and systemic manifestations listed in regulatory documents may include tremor, nervousness, headache, and seizures.

Physiologically, overdose has been formally associated with metabolic abnormalities, specifically hypokalemia (low serum potassium) and hyperglycemia (high blood glucose). The regulatory profile states that overdose carries a serious risk of life-threatening outcomes. Large doses are associated with clinically significant prolongation of the QTc interval, which creates the potential for producing ventricular arrhythmias and has been linked to fatalities in association with the excessive use of inhaled sympathomimetic drugs. A potential for increased systemic exposure exists in individuals with hepatic impairment due to the drug’s metabolic pathway.

When an overdose is suspected, immediate medical assessment is required. Official guidance mandates the immediate discontinuation of Salmeterol. Management involves providing appropriate symptomatic therapy and general supportive measures. Due to the documented cardiac risks, cardiac monitoring (ECG) and monitoring of serum potassium levels are essential procedural requirements.

Therapeutic Uses of Salmeter

Salmeterol is commonly used for the long-term maintenance treatment of chronic breathing disorders, where it may assist with managing symptoms and supporting general well-being during symptomatic phases.

The medication is used to help manage symptoms such as wheezing, shortness of breath, coughing, and chest tightness, and is commonly applied across conditions presenting with chronic breathing issues.


Easing Breathing Difficulties and Supporting Stability

This medicine is relevant for easing symptoms in conditions characterized by periods of heightened symptoms, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. It is applied in domains where symptom clusters may become intense or disruptive, helping to address symptoms that interfere with daily comfort.

“This medicine is commonly used to help with symptoms associated with physical activity, and may be part of symptomatic management in situations where symptoms are often provoked by exertion.”

By focusing on easing these symptoms, the medicine may assist with maintaining functional stability and contributes to easing the overall symptom load for patients managing these chronic conditions.

Quick Fact: Symptom Focus Salmeterol is commonly used to help with symptoms of increased physiological activity, such as wheezing and chest tightness, which interfere with daily functioning.

Regulatory References

  1. Salmeterol Oral Inhalation: MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Salmeterol is strictly defined by official regulatory documentation, primarily concerning age, specific co-treatment requirements, and acute clinical status.

Eligibility and Non-Eligibility Status

Classification Population or Condition Status
Absolute Contraindication Acute episodes of asthma or COPD (not a rescue medicine) Prohibited
Absolute Contraindication Asthma patients using Salmeterol alone (Monotherapy) Prohibited
Absolute Contraindication Known hypersensitivity to Salmeterol or excipients (e.g., severe milk protein allergy) Prohibited
Age Restriction Children younger than 4 years of age Not Established
Conditional Use Patients with asthma Must be used with an Inhaled Corticosteroid
Conditional Use Patients with severe hepatic disease Close Monitoring Required
Conditional Use Pregnancy or Lactation Use only if benefit outweighs risk
Caution Required Severe cardiovascular disorders, thyrotoxicosis, diabetes mellitus Eligible, but requires caution

Regulatory Context Summary

Regulatory documents strictly prohibit the use of Salmeterol for immediate symptom relief and contraindicate its use as a single treatment for asthma due to safety risks. Eligibility is generally established for adults and children aged 4 years and older, provided asthma patients receive concomitant inhaled corticosteroid therapy. Patients with certain metabolic or cardiovascular conditions are eligible but require careful oversight.

What should I know about interactions with other medicines?

This section outlines the officially documented interaction patterns for Salmeterol, the active ingredient in Salmeter, as stated in government regulatory documents.

Contraindicated and Restricted Combinations

Interaction Classification Interacting Product Category Constraint
Contraindicated Additional Long-Acting beta2-Agonists (LABAs) Do not use in combination due to the risk of excessive systemic beta-adrenergic stimulation, which may lead to overdose.
Use Not Recommended Strong CYP3A4 Inhibitors Avoid co-administration (e.g., Ritonavir, Ketoconazole) due to a documented increase in Salmeterol plasma exposure, which carries a risk of increased cardiovascular effects.

Pharmacodynamic and Cautionary Interactions

Interactions involving caution are based on potential additive effects or antagonism on body systems:

  • beta-Adrenergic Receptor Blocking Agents (Beta-blockers): Use requires caution, as these medicines may block the bronchodilatory effects and could precipitate severe bronchospasm.
  • Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): Use demands extreme caution, as these agents may potentiate Salmeterol’s effect on the vascular system.
  • Non–Potassium-Sparing Diuretics: Caution is necessary, as co-administration may worsen hypokalemia (low potassium) or electrocardiographic changes.

Other Documented Constraints

  • Dietary Restrictions: Advisories exist to avoid grapefruit and grapefruit juice, which acts as a strong CYP3A inhibitor and can increase systemic drug exposure.
  • Hepatic Impairment Note: The effects of Salmeterol may be increased in patients with liver disease because the medicine is predominantly cleared through hepatic metabolism.

The overall regulatory profile defines strict limits on co-administration to manage risks of antagonistic effects, vascular potentiation, and significant systemic exposure increases from strong metabolic inhibitors.

Mechanism of Action

The mechanism of action of Salmeterol involves its role as a selective agonist at the beta-2 adrenergic receptors (beta2-AR) on airway smooth muscle cells. The drug employs a unique lipophilic side-chain to anchor itself near the receptor for prolonged, sustained activation.

Sustained Activation of the beta2-AR Pathway

Salmeterol's binding initiates the G s protein/adenylyl cyclase cascade, causing a significant increase in the intracellular messenger cyclic AMP ( cAMP). This sustained molecular signaling establishes the sustained physiological state.

Inhibition of Contraction and Calcium Regulation

Elevated cAMP activates Protein Kinase A ( PKA), which in turn inhibits the myosin light-chain kinase ( MLCK) responsible for contraction and promotes the removal and sequestration of intracellular calcium ions ( Ca^2+). The simultaneous disruption of the contractile apparatus and reduction of Ca^2+ leads directly to the prolonged physiological state of reduced smooth muscle tension. The mechanism may also influence mast cell activity, which modulates the release of mediators that promote smooth muscle contraction.

Dosage and Administration Information

How to Use Salmeter: Official Administration Guidelines

This section describes the administration and dosing rules for Salmeterol xinafoate.

Feature Detail
Route of Administration Oral Inhalation only, delivered directly to the lungs via specialized devices, such as a dry powder inhaler.
Dosing Schedule Maintenance Dosing: One inhalation (50 mcg Salmeterol base). EIB Prevention Dosing: One inhalation (50 mcg).
Frequency and Timing Maintenance: Twice daily (bid), administered approximately 12 hours apart (morning and evening). EIB Prevention: Must be administered at least 30 minutes before exercise and not more than once every 12 hours.
Age-Group Rules Approved for use in patients 4 years of age and older. The dosage is the same for children 4 years and older as for adults. Safety and efficacy are not established for children under 4 years.
Missed-Dose Protocol If a regular dose is missed, the patient must skip the missed dose and take the next dose at the usual time. It is important not to take two doses at once.
Use Context Constraint The medicine is designated for long-term maintenance and must not be used for the immediate relief of acute or sudden breathing difficulties.

Connection to the Overall Use Protocol

These instructions establish a structured, time-dependent protocol based on a twice-daily frequency to ensure continuous support. This administration pattern defines the medicine's role as a scheduled component of a fixed regimen, contrasting it with medicines intended for immediate, on-demand use. The procedural rules for missed doses and maximum frequency are documented to ensure adherence to the maximum recommended dosage of one inhalation twice daily. The constraints confirm that the medicine is reserved for scheduled use, not for emergency or acute management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Salmeterol

Evidence for Maintenance Treatment in Chronic Obstructive Pulmonary Disease (COPD)

Research was studied for Salmeterol in the context of chronic obstructive pulmonary disease (COPD), a condition involving periods of heightened symptoms and functional limitations. The main research has relied on Randomized Controlled Trials (RCTs) and various observational cohort studies comparing the compound to inactive control groups or other studied comparators. The outcomes related to systemic or functional imbalance that were studied for included physiological lung function parameters (such as FEV1) and clinical event frequency, specifically monitoring the patterns of COPD exacerbations (flare-ups).

These research efforts describe patterns observed in the studies where measurements of lung function changed during the study period relative to the initial baseline measurements taken before treatment began. Furthermore, analyses of this evidence data describe patterns related to the frequency of exacerbations when compared to control groups.


Evidence for Maintenance Treatment in Asthma

The evidence base for asthma comprises multiple study types, including large-scale RCTs and long-term observational surveillance studies. This research was applied in studies examining patient-reported experiences when Salmeterol was evaluated in combination with an inhaled corticosteroid (ICS). The outcomes related to physical discomfort and respiratory function was studied for this use, examining changes in specific lung function markers and tracking outcomes describing episodic or acute changes.

However, studies exploring Salmeterol used alone (monotherapy) reported data related to serious clinical events that was associated with the use of the medicine when compared to inactive control. This particular finding informed specific considerations in regulatory use. For the combination therapy, the low frequency of rare but serious events means that the certainty remains low when comparing the relative risks of Salmeterol versus other long-acting agents in some clinical scenarios.


Research Gaps and Areas of Uncertainty

There are several areas where the research is limited or where long-term effects are not fully established. For COPD, the research does not determine how the medicine affects the long-term decline in lung function over many years, as follow-up durations were limited in many key RCTs. Data for children under four years old remain insufficient to draw broad conclusions about long-term risk profiles, and comparative evidence is lacking for some specific subgroups.

Frequently Asked Questions (FAQ)

Common questions about Salmeter (FAQ)


Q: What is the primary medical use for which Salmeter is officially approved?

A: According to official product information, Salmeterol is approved for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD). It is also approved for treating asthma, but only when used together with an inhaled corticosteroid. Additionally, it is used for the prevention of exercise-induced bronchospasm (EIB).


Q: How quickly does Salmeter start to take effect after the first use?

A: Studies indicate that a patient may begin to notice some improvement in symptom control within 30 minutes of administration. However, because Salmeter is a long-term maintenance medication, the maximum therapeutic benefit may not be fully achieved for a week or longer. The specific time it takes to work can vary among individuals.


Q: Has Salmeter been studied in diverse patient populations or ethnic groups?

A: Clinical trial data that led to the regulatory approval of Salmeterol included participants from different ethnic groups. Official documents note a finding in one specific clinical study of an increased risk for asthma-related death that was highest for African-American patients taking the drug without a corticosteroid.


Q: Are there any long-term health risks associated with continuous use of Salmeter?

A: Regulatory documents contain a Black Box Warning for long-acting beta2-agonists (LABAs) like Salmeterol. This warning indicates that these medicines, when used alone for asthma, may increase the risk of asthma-related death. The official product labeling states that the medication is recommended to be used only as long as necessary to achieve and maintain control of asthma symptoms.


Q: Does Salmeter contain lactose, gluten, or common allergens?

A: The inhalation powder formulation is documented to contain lactose monohydrate as an inactive ingredient. Official product information notes that the medicine is strictly prohibited (contraindicated) in people with a known hypersensitivity to any ingredient in the preparation, which includes severe milk protein allergy due to excipients.


Q: Is it considered normal to experience difficulty sleeping when on Salmeter?

A: According to official side-effect data, Salmeterol use can be associated with certain nervous system effects. These commonly include nervousness, and in some cases, difficulty falling asleep or staying asleep, which are categorized as sleep disorders. The full list of potential effects is detailed within the official product information.


Q: Can Salmeter be used by people with existing liver or kidney problems?

A: Official product information advises that caution is necessary for people with existing liver problems because the medicine is primarily processed by the liver. The potential for increased systemic exposure and side effects in cases of liver impairment is a key reason why careful monitoring by a healthcare professional is noted in regulatory information. There are no specific restrictions or dosing adjustments generally listed for kidney problems.


Q: Why is Salmeter taken at a specific time of day, such as morning or evening?

A: Salmeter is a long-acting medicine, with the effect of a single dose lasting for approximately 12 hours. The official frequency is twice daily, administered approximately 12 hours apart (morning and evening). This fixed, scheduled timing ensures the sustained bronchodilation needed to maintain continuous control of airway function over a full 24-hour period.


Q: Does Salmeter have any known interactions with over-the-counter pain relievers?

A: Regulatory documents contain a general advisory that healthcare professionals should be informed of all medicines being taken, including nonprescription (over-the-counter or OTC) products. This caution is necessary because some OTC products, such as certain pain relievers, may affect the body's mineral balance, specifically serum potassium levels, when taken with Salmeter.


Q: Are there any known issues with taking Salmeter alongside common vitamins or mineral supplements?

A: Official regulatory information notes that healthcare professionals should be informed about the use of all vitamins, herbal products, or supplements. This is relevant because Salmeterol can cause a documented decrease in potassium levels, and certain supplements could also influence the body’s mineral balance.


Q: What is the maximum duration for which Salmeter is typically prescribed?

A: For asthma treatment, official guidelines state that Salmeterol should only be used as long as necessary to bring symptoms under control. Once asthma symptoms are stable, a patient's doctor may recommend stopping Salmeterol use, though the inhaled corticosteroid is typically recommended to be continued. For COPD, the drug is intended for long-term maintenance.


Q: Are there different brand names and generic versions of Salmeter, and are they the same?

A: Yes, the active ingredient Salmeterol is available under multiple brand names and in combination products with other medicines. Regulatory authorities have approved generic versions of Salmeterol products, which are certified to meet the same strict quality and regulatory requirements as the brand-name drugs.


Q: What happens if a person suddenly stops taking Salmeter?

A: Official patient information contains a warning that the medication should not be discontinued without consultation with a healthcare provider. Since Salmeter is a long-term maintenance treatment, suddenly stopping its use can lead to the worsening of underlying symptoms and the return of breathing difficulties.


Q: Is Salmeter a controlled substance or has it been categorized as having potential for misuse?

A: According to official regulatory classification in the United States, Salmeterol is not categorized as a controlled substance under the Controlled Substances Act (CSA).


Q: Does Salmeter have an interaction warning regarding alcohol consumption?

A: While the primary interaction warnings focus on certain medications and grapefruit, regulatory interaction summaries do flag potential alcohol/food interactions in general. The need to discuss the use of alcohol with a healthcare professional to understand any potential systemic risks is often highlighted in patient information.


Q: Is it necessary to take Salmeter with or without food for best absorption?

A: The route of administration for Salmeter is oral inhalation, delivering the medicine directly to the lungs. Official patient information states that unless a doctor advises otherwise, patients are advised to continue their normal diet, as no specific food restrictions are mandated for the absorption or effectiveness of the inhaled medication.


Q: Where can a patient find the complete list of regulatory warnings for Salmeter?

A: Patients can access the complete and current official regulatory labeling information by visiting the websites of the relevant government regulatory authorities. For example, in the United States, the full drug label is accessible through the FDA's website, where the official prescribing information is maintained.

How should Salmeter be stored and disposed of?

How to Store and Dispose of Salmeterol Inhalation Powder

Official regulatory documents mandate strict storage and disposal requirements for Salmeterol inhalation powder to ensure product stability.

Required Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep in a dry place, away from direct heat and sunlight.
Packaging Store in the unopened foil pouch until initial use.

Stability and Disposal Rules

The device must be stored out of the reach of children. A strict shelf-life constraint applies after opening: the product must be discarded 1 month after removal from the foil pouch or when the dose counter reads “0,” whichever occurs first. For disposal, patients must ask a healthcare professional how to safely discard outdated or unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Salmeter found in:

A-Z Index: